Filing Overview
Pliant Therapeutics, Inc. filed a Form 8-K on August 11, 2020, under Item 2.02 to announce financial results for the quarter ended June 30, 2020. The filing furnishes an August 11, 2020 press release as Exhibit 99.1, but the provided filing text does not include the press release’s financial results.
Financial Metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, cash and investments, liquidity, or other financial metrics. These amounts should be obtained from Exhibit 99.1 or the related quarterly filing.
Changes, Outlook, and Risks
The provided text does not describe material changes versus the prior comparable period, management guidance, outlook, contingencies, risks, or unusual items. The filing is primarily a furnishing of the company’s quarterly-results press release.
Important Investor Verification Items
- Review Exhibit 99.1 for the quarter’s revenue, operating expenses, net loss, cash flow, and liquidity.
- Verify cash and investment balances, debt obligations, and the company’s stated operating runway.
- Review management’s discussion of clinical programs, development milestones, guidance, and financing needs.
- Confirm any material changes from the quarter ended June 30, 2019 and subsequent events disclosed in the related quarterly report.
- Note that the information in the Form 8-K and furnished exhibit is not deemed filed for purposes of Section 18 of the Exchange Act.